Investors - Corporate Partners

Endo Pharmaceuticals is a successful specialty pharmaceutical company that researches, develops and markets prescription pharmaceuticals used primarily to treat and manage pain, as well as prescription products in the neurology and supportive care oncology fields.

With a product portfolio that includes the Lidoderm^® patch, Opana^® ER and Opana^® tablets, Percocet^® tablets and Frova^® tablets, Endo is anchored in a strong commitment to the pain management market. We are seeking to expand our presence in neurology, supportive care oncology, and other specialty therapeutic areas.

Our 690-person sales force has a committed presence with physician audiences including pain specialists, anesthesiologists, neurologists, oncologists, surgeons and primary care physicians. Our scientific team has specialized knowledge in the developmental and regulatory challenges confronting the commercialization of products in these areas.

Endo's long-term growth strategy includes expanding sales of our established brand name products, developing proprietary products and selected generics that capitalize on our expertise in pain management, and related fields, acquiring and in-licensing products that leverage our core scientific and commercial strengths. Endo is actively seeking both marketed and development stage products in complementary areas.

For further information:

Endo has significant experience in structuring transactions for collaborative efforts in both development and marketing programs, and in managing such collaborative relationships; Endo was recognized for its capabilities in this regard in the 2007 Alliance Excellence Award program of the Association of Strategic Alliance Professionals (ASAP). To find out more about corporate development opportunities with Endo, please contact Bob Cobuzzi, Acting Head Corporate Development, at 610-558-9800, bd@endo.com.